Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 2,237 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $8.02, for a total value of $17,940.74. Following the sale, the chief executive officer now owns 489,697 shares in the company, valued at $3,927,369.94. This trade represents a 0.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Bicycle Therapeutics Stock Performance
Bicycle Therapeutics stock opened at $6.89 on Friday. The company has a market capitalization of $476.80 million, a price-to-earnings ratio of -2.09 and a beta of 1.40. The company's 50 day simple moving average is $10.77 and its 200-day simple moving average is $16.93. Bicycle Therapeutics plc has a 1 year low of $6.77 and a 1 year high of $28.67.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. During the same period in the prior year, the firm earned ($1.16) earnings per share. The business's revenue for the quarter was down 30.2% compared to the same quarter last year. Equities analysts expect that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.
Analysts Set New Price Targets
Several equities analysts have issued reports on BCYC shares. JMP Securities decreased their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC reiterated a "buy" rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and set a $33.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. B. Riley lowered their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, December 13th. Finally, Stephens reissued an "equal weight" rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.14.
View Our Latest Report on BCYC
Institutional Investors Weigh In On Bicycle Therapeutics
A number of hedge funds have recently bought and sold shares of BCYC. JPMorgan Chase & Co. grew its position in shares of Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after buying an additional 1,782 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after acquiring an additional 2,191 shares in the last quarter. Barclays PLC increased its position in shares of Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after purchasing an additional 2,345 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Bicycle Therapeutics by 18.9% in the 4th quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock valued at $336,000 after purchasing an additional 3,811 shares in the last quarter. Finally, Avior Wealth Management LLC purchased a new stake in shares of Bicycle Therapeutics during the 4th quarter worth $57,000. Institutional investors and hedge funds own 86.15% of the company's stock.
About Bicycle Therapeutics
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
